IPO Year: 2023
Exchange: NASDAQ
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/13/2024 | $28.00 | Outperform | Robert W. Baird |
6/6/2024 | $22.00 | Buy | H.C. Wainwright |
11/28/2023 | $20.00 | Overweight | JP Morgan |
11/28/2023 | $20.00 | Buy | Stifel |
11/28/2023 | $19.00 | Outperform | Leerink Partners |
11/28/2023 | $22.00 | Outperform | RBC Capital Mkts |
11/28/2023 | $23.00 | Buy | Chardan Capital Markets |
Robert W. Baird initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $28.00
H.C. Wainwright initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $22.00
JP Morgan initiated coverage of Lexeo Therapeutics with a rating of Overweight and set a new price target of $20.00
Stifel initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $20.00
RBC Capital Mkts initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $22.00
Leerink Partners initiated coverage of Lexeo Therapeutics with a rating of Outperform and set a new price target of $19.00
Chardan Capital Markets initiated coverage of Lexeo Therapeutics with a rating of Buy and set a new price target of $23.00
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo's ongoing SUNRISE-FA Phase 1/2 clinical
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
3 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
4 - Lexeo Therapeutics, Inc. (0001907108) (Issuer)
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 Cash and cash equivalents of $175.0 million expected to provide operational runway into 2027 NEW YORK, Aug. 12, 2024 (GLOBE N
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive Officer of argenx SE, as an independent, non-executive director to its Board of Directors. Mr. Van Hauwermeiren is a seasoned biotech executive with over two decades of experience in both general management and business development across the life sciences and consumer goods industries. "Tim is a highly accomplished life-sciences entrepreneur who has built one of Europe's most successful biotech companies, and I am thrilled to welcome him to our Board of Directors," said R. N
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $22 price target.
Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $23 price target.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index rising more than 150 points on Monday. The Dow traded up 0.44% to 40,178.06 while the NASDAQ rose 0.29% to 18,451.73. The S&P 500 also rose, gaining, 0.25% to 5,629.59. Check This Out: Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging SectorsEnergy shares jumped by 2% on Monday. In trading on Monday, utilities shares fell by 1.8%. Top Headline Goldman Sachs Group Inc. (NYSE:GS) reported better-than-expected results for its second quarter. Goldman posted revenue of $12.730 billion for the second quarter, beating the consensus of $12.456 billion.
Shares of SolarEdge Technologies, Inc. (NASDAQ:SEDG) fell sharply during Monday's session after the company announced a workforce reduction. SolarEdge disclosed a decision to lay off 400 employees. The company stated that 200 of these job cuts are in Israel. The action involves reducing headcount and discretionary spending across all departments. SolarEdge Technologies shares dipped 12.2% to $27.77 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Autonomix Medical, Inc. (NASDAQ:AMIX) shares climbed 148% to $1.4850 after the company entered into an agreement with RF Innovations to license intellectual property for its Apex 6 Radiofrequency Gener
U.S. stocks traded higher midway through trading, with the Nasdaq Composite rising more than 200 points on Monday. The Dow traded up 0.73% to 40,291.69 while the NASDAQ rose 1.16% to 18,611.47. The S&P 500 also rose, gaining, 0.81% to 5,660.67. Check This Out: Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging SectorsEnergy shares jumped by 1.6% on Monday. In trading on Monday, utilities shares fell by 2.1%. Top Headline The NY Empire State Manufacturing Index fell to a reading of -6.6 in July, compared to market estimates of -6. Equities Trading UP Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) sh
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 200 points on Monday. Following the market opening Monday, the Dow traded up 0.62% to 40,249.41 while the NASDAQ rose 0.52% to 18,493.58. The S&P 500 also rose, gaining, 0.44% to 5,639.94. Check This Out: Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging SectorsInformation technology shares jumped by 1.1% on Monday. In trading on Monday, utilities shares fell by 1.3%. Top Headline The NY Empire State Manufacturing Index fell to a reading of -6.6 in July, compared to market estimates of -6. Equities Trading UP Scina
Across both the Lexeo SUNRISE-FA Phase 1/2 clinical trial and the Weill Cornell Medicine investigator-initiated Phase 1A trial, LX2006 was well tolerated with no treatment-related serious adverse events, and clinically meaningful improvements in cardiac biomarkers were observed with increasing improvement over time. "Based on the favorable safety profile and clinical benefits observed to date, we are excited to explore expedited clinical development of LX2006, including potential for accelerated approval of this possibly life-saving treatment." Interim Safety Results LX2006 was well tolerated with no treatment-related serious adverse events to date in either study No signs of complemen
Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo's ongoing SUNRISE-FA Phase 1/2 clinical trial (NCT05445323) and the ongoing Weill Corn
Announced positive interim data from Phase 1/2 studies in Friedreich ataxia (FA) cardiomyopathy, which showed LX2006 was well tolerated with no treatment-related serious adverse events and demonstrated evidence of sustained and consistent treatment effect across multiple cardiac measures Recently initiated formal engagements with FDA on surrogate endpoints for LX2006 registrational study; expects to provide update by end of year Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 Cash and cash equivalents of $175.0 million expected to provide operational runway into 2027 NEW YORK, Aug. 12, 2024 (GLOBE N
Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants with elevated LVMI at baseline >10% reduction in LVMI at 12 months in 75% of participants with elevated LVMI at baseline Sustained and consistent improvements in other key measures of cardiac status, including left ventricular wall thickness and troponin I, in majority of participants at 12 months Increased post-treatment frataxin expression above baseline in all participants evaluated via myocardial biopsy to date LX2006 was well tolerated with no treatment-related serious adverse events to date; proceeding to Cohort 3 in SUNRISE-FA, with one
NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia (FA) cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo's ongoing SUNRISE-FA Phase 1/2 clinical
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company, today announced the appointment of Tim Van Hauwermeiren, co-founder and Chief Executive Officer of argenx SE, as an independent, non-executive director to its Board of Directors. Mr. Van Hauwermeiren is a seasoned biotech executive with over two decades of experience in both general management and business development across the life sciences and consumer goods industries. "Tim is a highly accomplished life-sciences entrepreneur who has built one of Europe's most successful biotech companies, and I am thrilled to welcome him to our Board of Directors," said R. N
Closed an oversubscribed $95 million equity financing in March with Q1 2024 cash balance of $195.1 million at quarter-end, expected to provide runway into 2027 Completed in-license agreement with Cornell University for intellectual property rights, including current and future clinical data from an ongoing investigator-initiated trial of AAVrh.10hFXN (LX2006) to support regulatory discussions Interim readout of combined data set of LX2006 at multiple doses anticipated in mid-2024; Lexeo expects to provide analysis of natural history data and baseline characteristics of these study participants in advance of interim readout Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruit
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that company management will participate in fireside chats at the following investor conferences: The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 9:00 AM ETRBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14, 2024 at 11:00 AM ETBank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:40 AM PT The events will be webcast live under the News & Events tab
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN (LX2006) to support regulatory discussions Together with Lexeo Therapeutics' ongoing study of LX2006, a total of 11 participants have been treated to date; includes patients at treatment durations out to 18-months with no treatment-related serious adverse events observed across either study Interim readout of combined data set at multiple doses expected mid-year 2024 NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine compa
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LX2006, the company's AAVrh.10hFXN-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy. LX2006 is designed to deliver a functional frataxin gene to promote frataxin protein expression and restore mitochondrial function in myocardial cells. Fast Track is a process designed to facilitate the development and ex
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced the closing of its previously announced private placement. The financing was co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management, Novo Holdings A/S, Invus, Laurion Capital Management, Longitude Capital, Omega Funds and Woodline Partners LP for total gross proceeds of approximately
Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data from a subset of the second dose cohort of SUNRISE-FA, a Phase 1/2 clinical trial of LX2006 for the treatment of Friedreich's ataxia (FA) cardiomyopathy, showing positive change in post-treatment frataxin levels Additional interim data readout from SUNRISE-FA expected in mid-2024, with follow-up out to one year from the low-dose and multiple time points of follow-up expected from at least three patients treated at the mid-dose Initiated SNAPSHOT-PKP2, a natural history study designed to evalua
SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
SC 13G/A - Lexeo Therapeutics, Inc. (0001907108) (Subject)
424B3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)
10-Q - Lexeo Therapeutics, Inc. (0001907108) (Filer)
8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
424B3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)
8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
424B3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)
8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
424B3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)
8-K - Lexeo Therapeutics, Inc. (0001907108) (Filer)
424B3 - Lexeo Therapeutics, Inc. (0001907108) (Filer)